Tazemetostat Gets Second Fast-Track Designation from FDA

The U.S. Food and Drug Administration (FDA) has granted fast-track designation to tazemetostat, an EZH2 inhibitor, for the treatment of patients with relapsed or refractory follicular lymphoma with either wild-type EZH2 or EZH2-activating mutations.

Tazemetostat is currently being studied in ongoing clinical phase II trials of patients with follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).

The FDA previously granted tazemetostat fast-track designation for relapsed/refractory DLBCL with EZH2-activating mutations.

Source: Epizyme press release, April 25, 2017.